Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Hodgkin Lymphoma, Lymphoid Malignancies, Myelodysplastic Syndromes, Myelofibrosis, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Non-Hodgkin Lymphoma
Conditions
Keywords
Total Body Irradiation, Human Mesenchymal Stromal Cells, hMSC, Cyclophosphamide, Fludarabine, Dimethyl Sulfoxide, DMSO, Cyclosporine, Mycophenolate Mofetil, MMF, Granulocyte- Colony Stimulating Factor, G-CSF, GVHD, Cancer, feasibility
Brief summary
This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil at the time of transplant may stop this from happening.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the feasibility of combining intra-osseous umbilical cord blood (UCB) hematopoietic stem cells and human mesenchymal stromal cells (hMSC) following reduced intensity conditioning (RIC). SECONDARY OBJECTIVES: I. To estimate the time to engraftment of intra-osseous (IO) UCB transplant combined with hMSC following RIC. II. To estimate the safety profile of IO UBC transplant combined with hMSC. OUTLINE: REDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide intravenously (IV) over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total body irradiation (TBI) on day -1. GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine orally (PO) or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO twice daily (BID) on days -5 to 100. TRANSPLANT: Patients undergo intra-osseous UCB and hMSC co-transplant on day 0. After completion of study treatment, patients are followed up at days 28 and 100, and then at 6, 9, and 12 months.
Interventions
DRUGcyclophosphamide
All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
DRUGfludarabine phosphate
Given by IV during prep at 40mg/m2 for 5 days
RADIATIONtotal-body irradiation
Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
DRUGcyclosporine
Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
DRUGmycophenolate mofetil
Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
PROCEDUREumbilical cord blood transplantation
Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
Sponsors
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have one of the following malignancies: * Acute myelogenous leukemia (AML): high-risk AML including: * Antecedent hematological disease (e.g., myelodysplasia \[MDS\]) * Treatment-related leukemia * Complete remission (first complete remission \[CR1\]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 \[Flt 3\] mutation, 11q23, del 5, del 7, complex cytogenetics) * Second complete remission (CR2) or third complete remission (CR3) * Induction failure or first relapse with either * ≤ 10% blasts in the marrow and/or * ≤ 5% blasts in the peripheral blood * Acute lymphoblastic leukemia (ALL) * High-risk CR1 including: * Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements) * Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy * No complete remission (CR) within 4 weeks of initial treatment * Induction failure * CR2 or CR3 with either: * ≤ 10% blasts in the marrow and/or * ≤ 5% blasts in the peripheral blood * Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therapy * Myelofibrosis (MF): * Intermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS)-plus * Monosomal karyotype * Presence of inv(3)/i(17q) abnormalities * Other unfavorable karyotype OR leukocytes ≥40 X 10\^9/L AND * Circulating blasts ≤ 9% * Relapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia) meeting the following criteria: * Disease status: stable disease, partial remission or 2nd and 3rd complete remission * Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as: * Blast count ≥ 20% in the peripheral blood or bone marrow * Large foci of blasts on bone marrow * Presence of extra-medullary blastic infiltrate (myeloid sarcoma or chloroma) * Recipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Candidates for reduced intensity conditioning regimens * Patients who do not have HLA-matched (defined as matched in HLA A, B, C, and DRB1) related or unrelated donors, those who elect to undergo UCB even if they have a MRD or MUD, or patients who require a UCB either for emergency indications such as primary graft failure. * Cord Blood Units available through NMDP with the following minimal criteria: * HLA Match: 4/6 or better match (HLA A, B, DRB1) * Cell dose: Minimum of 2.0x107TNC/kg pre thaw * Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma: concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated; such treatment may continue until the planned course is completed; subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement * Subjects must have a back-up umbilical cord on the registry in addition to the umbilical cord being used in this study * Subjects must have the ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients with inadequate Organ Function as defined by: * Creatinine clearance \< 30 ml/min * Bilirubin ≥ 2 x institutional upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) ≥ 2 x institutional upper limit of normal * Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≥ 2 x institutional upper limit of normal * Corrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) \< 40% normal * Left ventricular ejection fraction \< 35% * Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or breastfeeding women are excluded from this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with BM cellularity failure: Measure of feasibility | 42 days after transplant | Primary graft failure is defined by \<10% BM cellularity in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment |
| Number of patients with ANC failure without evidence of disease: Measure of feasibility | 42 days after transplant | Primary graft failure is defined by \<500 ANC cell/ul in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment |
| Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility | 42 days after transplant | Primary graft failure is defined by hematopoietic recovery with \<10% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median time of neutrophil recovery | Up to 12 months | The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier. |
| Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 | Up to 12 months | Descriptive statistics will be used. |
| Median time of platelet recovery | Up to 12 months | The median time of platelet recovery will be estimated using the methods of Kaplan and Meier. |
| Rate of neutrophil recovery | Up to 12 months | The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier. |
| Rate of platelet recovery | Up to 12 months | The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier. |
Countries
United States
Outcome results
None listed